• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种灵敏的生物标志物糖基化检测方法显示,与良性前列腺增生相比,前列腺癌患者的前列腺特异性抗原(PSA)糖基化程度增加。

A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia.

机构信息

Department of Molecular and Applied Biosciences, University of Westminster, London, UK.

出版信息

Clin Chim Acta. 2010 Dec 14;411(23-24):1935-9. doi: 10.1016/j.cca.2010.08.009. Epub 2010 Aug 12.

DOI:10.1016/j.cca.2010.08.009
PMID:20708609
Abstract

BACKGROUND

Prostate specific antigen (PSA) measurement is used for the diagnosis of prostate cancer (PCa) but the test lacks specificity due to the number of false positive readings. The glycosylation of PSA is altered in PCa but studies in this area have been limited to few clinical samples and/or require advanced laboratory facilities. An assay to assess PSA glycosylation was established using equipment available in most routine biomedical testing laboratories.

METHODS

Serum samples from patients with PCa or benign prostatic hyperplasia (BPH) were used. PSA (range 4-10 ng/ml) was affinity purified, separated and probed with the lectin Ulex europaeus (UEA-1; specific for α1,2 linked fucose). An enzyme-linked immunosorbent lectin assay (ELLA) with colorimetric detection was devised and PSA fucosylation assessed in a further independent set of 26 samples.

RESULTS

Free PSA (fPSA) from PCa patients showed a significant increase in fucosylation compared with fPSA from patients with BPH. The ELLA was 92% specific and 69% sensitive for PCa over BPH. In comparison, fPSA measurement was 70% specific and 56% sensitive (threshold set to 25% tPSA) for PCa over BPH.

CONCLUSIONS

Changes in glycosylation of PSA were identified using 50 μl of serum with PSA in the range of 4-10 ng/ml, this represents a more specific and sensitive test for PCa based on fucosylation changes of fPSA.

摘要

背景

前列腺特异性抗原(PSA)检测用于诊断前列腺癌(PCa),但由于假阳性读数较多,该检测缺乏特异性。PCa 中 PSA 的糖基化发生改变,但该领域的研究仅限于少数临床样本,并且/或者需要先进的实验室设备。本研究建立了一种使用大多数常规生物医学检测实验室都具备的设备评估 PSA 糖基化的检测方法。

方法

使用来自 PCa 或良性前列腺增生(BPH)患者的血清样本。PSA(范围 4-10ng/ml)经亲和纯化、分离后用荆豆凝集素(UEA-1;特异性识别α1,2 连接的岩藻糖)进行探测。设计了一种酶联免疫吸附凝集素检测法(ELLA),并采用比色法检测,进一步在 26 份独立样本中评估 PSA 岩藻糖基化。

结果

与 BPH 患者的 fPSA 相比,PCa 患者的游离 PSA(fPSA)的岩藻糖基化显著增加。ELLA 对 PCa 与 BPH 的区分特异性为 92%,敏感性为 69%。相比之下,fPSA 检测法对 PCa 与 BPH 的区分特异性为 70%,敏感性为 56%(阈值设定为 25%总 PSA)。

结论

使用 50μl 血清和 4-10ng/ml 范围内的 PSA 可鉴定 PSA 糖基化的改变,基于 fPSA 岩藻糖基化改变,该检测法对 PCa 具有更高的特异性和敏感性。

相似文献

1
A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia.一种灵敏的生物标志物糖基化检测方法显示,与良性前列腺增生相比,前列腺癌患者的前列腺特异性抗原(PSA)糖基化程度增加。
Clin Chim Acta. 2010 Dec 14;411(23-24):1935-9. doi: 10.1016/j.cca.2010.08.009. Epub 2010 Aug 12.
2
Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns.良性前列腺增生和前列腺癌中尿前列腺特异性抗原的糖基化:通过凝集素结合模式进行评估。
Clin Biochem. 2005 Jan;38(1):58-65. doi: 10.1016/j.clinbiochem.2004.09.022.
3
Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.良性和恶性前列腺疾病中前列腺特异性抗原与α1-蛋白酶抑制剂复合物的表征与测定
Scand J Clin Lab Invest Suppl. 2000;233:51-8.
4
alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.α1,2-岩藻糖化和β-N-乙酰半乳糖胺化前列腺特异性抗原作为前列腺癌的有效标志物。
Glycobiology. 2010 Jan;20(4):452-60. doi: 10.1093/glycob/cwp197. Epub 2009 Dec 11.
5
Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.前列腺癌血清中前列腺特异性抗原的不同聚糖结构与精浆前列腺特异性抗原的关系
Glycobiology. 2006 Feb;16(2):132-45. doi: 10.1093/glycob/cwj042. Epub 2005 Sep 21.
6
The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.人腺体激肽释放酶的重要性及其在前列腺癌检测中与不同前列腺特异性抗原血清形式的相关性。
Cancer. 1998 Dec 15;83(12):2540-7.
7
Multigene methylation analysis for detection and staging of prostate cancer.用于前列腺癌检测和分期的多基因甲基化分析
Clin Cancer Res. 2005 Sep 15;11(18):6582-8. doi: 10.1158/1078-0432.CCR-05-0658.
8
Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.通过检测血清中人腺激肽释放酶2(HK2)来鉴别前列腺癌男性与良性疾病男性。
J Urol. 2000 Jan;163(1):311-6.
9
Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.与良性前列腺增生相比,前列腺癌患者血清 N-糖组中的核心岩藻糖基化和α2-3 唾液酸化显著增加。
Glycobiology. 2011 Feb;21(2):195-205. doi: 10.1093/glycob/cwq147. Epub 2010 Sep 22.
10
Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.前列腺癌与良性前列腺增生中碳水化合物结构及前列腺特异性抗原与龙牙豆凝集素的差异结合
Glycobiology. 2004 Aug;14(8):671-9. doi: 10.1093/glycob/cwh071. Epub 2004 Mar 24.

引用本文的文献

1
Development of a first-in-class antibody and a specific assay for α-1,6-fucosylated prostate-specific antigen.开发一种一流的抗体和针对α-1,6-岩藻糖基化前列腺特异性抗原的特异性检测方法。
Sci Rep. 2024 Jul 17;14(1):16512. doi: 10.1038/s41598-024-67545-1.
2
Integrins are enriched on aberrantly fucosylated tumour-derived urinary extracellular vesicles.整合素在异常岩藻糖基化的肿瘤来源的尿液细胞外囊泡中富集。
J Extracell Biol. 2022 Oct 10;1(10):e64. doi: 10.1002/jex2.64. eCollection 2022 Oct.
3
Decoding the glycoproteome: a new frontier for biomarker discovery in cancer.
解析糖蛋白质组学:癌症生物标志物发现的新领域。
J Hematol Oncol. 2024 Mar 22;17(1):12. doi: 10.1186/s13045-024-01532-x.
4
Capitalizing glycomic changes for improved biomarker-based cancer diagnostics.利用糖组学变化改进基于生物标志物的癌症诊断
Explor Target Antitumor Ther. 2023;4(3):366-395. doi: 10.37349/etat.2023.00140. Epub 2023 Jun 28.
5
Abnormal sialylation and fucosylation of saliva glycoproteins: Characteristics of lung cancer-specific biomarkers.唾液糖蛋白的异常唾液酸化和岩藻糖基化:肺癌特异性生物标志物的特征
Curr Res Pharmacol Drug Discov. 2021 Dec 20;3:100079. doi: 10.1016/j.crphar.2021.100079. eCollection 2022.
6
Fucosylation in Urological Cancers.尿路上皮癌中的岩藻糖基化。
Int J Mol Sci. 2021 Dec 11;22(24):13333. doi: 10.3390/ijms222413333.
7
Mass Spectrometry-Based Glycoproteomics and Prostate Cancer.基于质谱的糖蛋白质组学与前列腺癌。
Int J Mol Sci. 2021 May 14;22(10):5222. doi: 10.3390/ijms22105222.
8
Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies.验证游离前列腺特异性抗原糖型作为前列腺癌生物标志物以避免不必要的活检和再次活检。
Cancers (Basel). 2020 Oct 15;12(10):2988. doi: 10.3390/cancers12102988.
9
Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review.区分良性前列腺增生与前列腺癌的生物标志物:文献综述
Cancer Manag Res. 2020 Jul 1;12:5225-5241. doi: 10.2147/CMAR.S250829. eCollection 2020.
10
Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer.前列腺特异性抗原糖蛋白分析作为前列腺癌的诊断和预后生物标志物
Interface Focus. 2019 Apr 6;9(2):20180077. doi: 10.1098/rsfs.2018.0077. Epub 2019 Feb 15.